Home » Stocks » DMTK

DermTech, Inc. (DMTK)

Stock Price: $12.00 USD -0.23 (-1.88%)
Updated Oct 28, 2020 2:01 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 234.01M
Revenue (ttm) 4.56M
Net Income (ttm) -27.26M
Shares Out 19.50M
EPS (ttm) -3.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $12.00
Previous Close $12.23
Change ($) -0.23
Change (%) -1.88%
Day's Open 12.13
Day's Range 11.55 - 12.20
Day's Volume 44,965
52-Week Range 6.09 - 16.95

More Stats

Market Cap 234.01M
Enterprise Value 172.91M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.50M
Float 13.95M
EPS (basic) -1.99
EPS (diluted) -3.34
FCF / Share -2.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 320,980
Short Ratio 2.57
Short % of Float 2.30%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 51.38
PB Ratio 4.30
Revenue 4.56M
Operating Income -27.70M
Net Income -27.26M
Free Cash Flow -32.89M
Net Cash 61.10M
Net Cash / Share 3.13
Gross Margin 1.32%
Operating Margin -608.17%
Profit Margin -598.40%
FCF Margin -722.04%
ROA -51.23%
ROE -120.52%
ROIC 1,210.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.33*
(77.75% upside)
Low
20.0
Current: $12.00
High
24.0
Target: 21.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182016
Revenue3.362.44-
Revenue Growth37.76%--
Gross Profit0.06-0.19-
Operating Income-17.61-8.56-
Net Income-19.69-10.00-
Shares Outstanding7.014.413.75
Earnings Per Share-2.81-2.27-
Operating Cash Flow-17.79-7.61-
Capital Expenditures-0.21-0.01-
Free Cash Flow-18.00-7.62-
Cash & Equivalents15.374.750.03
Total Debt-5.540.17
Net Cash / Debt15.37-0.78-0.14
Assets18.215.660.19
Liabilities5.7211.020.17
Book Value12.49-5.360.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name DermTech, Inc.
Country United States
Employees 60
CEO John D. Dobak

Stock Information

Ticker Symbol DMTK
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: DMTK

Description

DermTech, a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.